Pretreatment of mesenchymal stem cells with angiotensin II enhances paracrine effects, angiogenesis, gap junction formation and therapeutic efficacy for myocardial infarction

International Journal of Cardiology

Volumn 188, Issue 1, 2015, Pages 22-32

  Liu, Chao ^a   Fan, Yue ^a   Zhou, Lu ^a   Zhu, Hong Yi ^a   Song, Yi Chen ^a   Hu, Liang ^a   Wang, Yu ^a   Li, Qing Ping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Angiotensin II; Mesenchymal stem cells; Myocardial infarction; Pretreatment; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN II; CONNEXIN 43; VASCULOTROPIN; VON WILLEBRAND FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL HYPOXIA; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GAP JUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; MESENCHYMAL STEM CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; STEM CELL TRANSPLANTATION; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; ECHOCARDIOGRAPHY; ECHOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MYOCARDIAL INFARCTION; NEEDLE BIOPSY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FEMALE; GAP JUNCTIONS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929302745     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.425     Document Type: Article

References (29)

1. D.Lloyd-Jones, R.Adams, M.Carnethon, et al.,Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation 119 (2009) 480-486, http://dx.doi.org/10.1161/CIRCULATIONAHA.108.191259.
2. S.Chen, W.Fang, F.Ye, Y.-H.Liu, J.Qian, S.Shan, J.Zhang, R.Z.Chunhua, L.Liao, S.Lin,J. Sun, Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction, Am. J. Cardiol. 94 (2004) 92-95, http://dx.doi.org/10.1016/j.amjcard.2004.03.034.
3. D. Orlic, J. Kajstura, S. Chimenti, I. Jakoniuk, S.M. Anderson, B. Li, J. Pickel, R. McKay, B. Nadal-Ginard, D.M. Bodine, A. Leri, P. Anversa, Bone marrow cells regenerate infarcted myocardium, Nature 410 (2001) 701-705, http://dx.doi.org/10.1038/35070587.
4. J. Chen, A.R. Baydoun, R. Xu, L. Deng, X. Liu, W. Zhu, L. Shi, X. Cong, S. Hu, X. Chen, Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis, Stem Cells 26 (2008) 135-145, http://dx.doi.org/10.1634/stemcells.2007-0098.
5. C.E. Murry, M.H. Soonpaa, H. Reinecke, H. Nakajima, H.O. Nakajima, M. Rubart, K.B.S. Pasumarthi, J.I. Virag, S.H. Bartelmez, V. Poppa, G. Bradford, J.D. Dowell, D.A. Williams, L.J. Field, Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts, Nature 428 (2004) 664-668, http://dx.doi.org/10.1038/nature02446.
6. A.A.Mangi,N.Noiseux,D.Kong,H.He,M.Rezvani,J.S.Ingwall,V.J.Dzau,Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts, Nat. Med. 9 (2003) 1195-1201, http://dx.doi.org/10.1038/nm912.
7. J.-Y. Hahn, H.-J. Cho, H.-J. Kang, T.-S. Kim, M.-H. Kim, J.-H. Chung, J.-W. Bae, B.-H. Oh, Y.-B. Park, H.-S. Kim, Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction, J. Am. Coll. Cardiol. 51 (2008) 933-943, http://dx.doi.org/10.1016/j.jacc.2007.11.040.
8. W.B. Strawn, R.S. Richmond, E. Ann Tallant, P.E. Gallagher, C.M. Ferrario, Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells, Br. J. Haematol. 126 (2004) 120-126, http://dx.doi.org/10.1111/j.1365-2141.2004.04998.x.
9. J. Xu, O.A. Carretero, C.-X. Lin, M.A. Cavasin, E.G. Shesely, J.J. Yang, T.L. Reudelhuber, X.-P. Yang, Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction, Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H1900-H1907, http://dx.doi.org/10.1152/ajpheart.00379.2007.
10. R.-Z. Shi, J.-C. Wang, S.-H. Huang, X.-J. Wang, Q.-P. Li, Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells, Exp. Cell Res. 315 (2009) 10-15, http://dx.doi.org/10.1016/j.yexcr.2008.09.024.
11. E.J. Gang, J.A. Jeong, S. Han, Q. Yan, C.-J. Jeon, H. Kim, In vitro endothelial potential of human UC blood-derived mesenchymal stem cells, Cytotherapy 8 (2006) 215-227, http://dx.doi.org/10.1080/14653240600735933.
12. T.Kinnaird,E.Stabile,M.S.Burnett,S.E.Epstein,Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences, Circ. Res. 95 (2004) 354-363, http://dx.doi.org/10.1161/01.RES.0000137878.26174.66.
13. D.W. Losordo, S. Dimmeler, Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies, Circulation 109 (2004) 2692-2697, http://dx.doi.org/10.1161/01.CIR.0000128596.49339.05.
14. C. Toma, M.F. Pittenger, K.S. Cahill, B.J. Byrne, P.D. Kessler, Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart, Circulation 105 (2002) 93-98, http://dx.doi.org/10.1161/hc0102.101442.
15. C.-X.Luo,Y.-H.Lin,X.-D.Qian,Y.Tang,H.-H.Zhou,X.Jin,H.-Y.Ni,F.-Y.Zhang,C.Qin,F.Li, Y. Zhang, H.-Y. Wu, L. Chang, D.-Y. Zhu, Interaction of nNOS with PSD-95 negatively controls regenerative repair after stroke, J. Neurosci. 34 (2014) 13535-13548, http://dx.doi.org/10.1523/JNEUROSCI.1305-14.2014.
16. H. Fujita, Y. Ishizaki, A. Yanagisawa, I. Morita, S.I. Murota, K. Ishikawa, Possible involvement of a chloride-bicarbonate exchanger in apoptosis of endothelial cells and cardiomyocytes, Cell Biol. Int. 23 (1999) 241-249, http://dx.doi.org/10.1006/cbir.1999.0342.
17. J.-Y. Hahn, H.-J. Cho, J.-W. Bae, H.-S. Yuk, K.-I. Kim, K.-W. Park, B.-K. Koo, I.-H. Chae, C.-S. Shin, B.-H. Oh, Y.-S. Choi, Y.-B. Park, H.-S. Kim, Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts, J. Biol. Chem. 281 (2006) 30979-30989, http://dx.doi.org/10.1074/jbc.M603916200.
18. C.-I. Cheng, C.-C. Hsiao, S.-C. Wu, S.-Y. Peng, H.-K. Yip, M. Fu, F.-S. Wang, Valsartan impairs angiogenesis of mesenchymal stem cells through Akt pathway, Int. J. Cardiol. (2012)http://dx.doi.org/10.1016/j.ijcard.2012.06.128.
19. S. Rosenkranz, TGF-beta1 and angiotensin networking in cardiac remodeling, Cardiovasc. Res. 63 (2004) 423-432, http://dx.doi.org/10.1016/j.cardiores.2004.04.030.
20. P.G. Steg, S.K. James, D. Atar, et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, Eur. Heart J. 33 (2012) 2569-2619, http://dx.doi.org/10.1093/eurheartj/ehs215.
21. B. Dawn, Preconditioning by angiotensin II: a tale of more than two kinases, J. Mol. Cell. Cardiol. 41 (2006) 223-225, http://dx.doi.org/10.1016/j.yjmcc.2006.05.005.
22. M.R. Abraham, G. Gerstenblith, Preconditioning stem cells for cardiovascular disease: an important step forward, Circ. Res. 100 (2007) 447-449, http://dx.doi.org/10.1161/01.RES.0000260272.21605.c8.
23. S.-W. Kim, H.-Z. Zhang, C.-E. Kim, J.-M. Kim, M.H. Kim, Amniotic mesenchymal stem cells with robust chemotactic properties are effective in the treatment of a myocardial infarction model, Int. J. Cardiol. 168 (2013) 1062-1069, http://dx.doi.org/10.1016/j.ijcard.2012.11.003.
24. M. Horiuchi, J. Iwanami, M. Mogi, Regulation of angiotensin II receptors beyond the classical pathway, Clin. Sci. (Lond.) 123 (2012) 193-203, http://dx.doi.org/10.1042/CS20110677.
25. Chao Liu, Jing-Wen Zhang, Liang Hu, Yi-Chen Song, Lu Zhou, Yue Fan, Hong-Yi Zhu, Yu Wang, Qing-Ping Li, Activation of the AT1R/HIF-1/ACE axis mediates angiotensin IIinduced VEGF synthesis in mesenchymal stem cells, Biomed. Res. Int. (2014)http://dx.doi.org/10.1155/2014/627380.
26. G. Yang, J. Tian, C. Feng, L. Zhao, Z. Liu, J. Zhu, Trichostatin a promotes cardiomyocyte differentiation of rat mesenchymal stem cells after 5-azacytidine induction or during coculture with neonatal cardiomyocytes via a mechanism independent of histone deacetylase inhibition, Cell Transplant. 21 (2012) 985-996, http://dx.doi.org/10.3727/096368911X593145.
27. S. Mohanty, S. Bose, K.G. Jain, B. Bhargava, B. Airan, TGFβ1 contributes to cardiomyogenic-like differentiation of human bone marrow mesenchymal stem cells, Int. J. Cardiol. 163 (2013) 93-99, http://dx.doi.org/10.1016/j.ijcard.2011.08.003.
28. J.-W. Shin, J. Swift, I. Ivanovska, K.R. Spinler, A. Buxboim, D.E. Discher, Mechanobiology of bone marrow stem cells: from myosin-II forces to compliance of matrix and nucleus in cell forms and fates, Differentiation 86 (2013) 77-86, http://dx.doi.org/10.1016/j.diff.2013.05.001.
29. J.M. Nygren, S. Jovinge, M. Breitbach, P. Säwén, W. Röll, J. Hescheler, J. Taneera, B.K. Fleischmann, S.E.W. Jacobsen, Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation, Nat. Med. 10 (2004) 494-501, http://dx.doi.org/10.1038/nm1040.